Answers are grounded in this paper and cite their sources.
The progression of malignancy depends entirely on profound restructuring of cells metabolic framework, allowing tumors to bypass physiological limitations while sustaining constant anabolic growth. Alteration of metabolic networks favour Warburg effect to speed structural biomass production and maximizing ATP production. Key oncogenic drivers such as MYC, KRAS and HIF1 cancer cells accelerate glycolysis, directly triggering rapid lactate secretion and altering the extracellular niche. The resulting acidification drives invasion and angiogenesis while dismantling immune defences, supressing cytotoxic T lymphocytes and fostering immunosuppressive myeloid populations. Besides altered glycolysis, cancer cells actively rewire metabolism of lipids, amino acids, and nucleic acids. By hijacking processes such as de novo lipogenesis and glutamine dependency, cancers acquire nitrogen- and carbon-building blocks to stabilise redox balance and fuel unchecked expansion. A critical frontier in modern oncology is identifying unique metabolic weaknesses of cancer stem cells (CSC). These quiescent, tumor seeding sub populations exhibit remarkable adaptability, seamlessly shifting between oxidative phosphorylation and glycolysis to survive microenvironment fluctuations and resist therapeutic interventions. To maintain their undifferentiated state, endure DNA replication stress and counteract damaging reactive oxygen species, these cancer stem cells rely on enhancing fatty acid oxidation, nucleotide salvage mechanisms and branched chain amino acid degradation and nucleotide salvage mechanisms. Modern therapies are transitioning away from broad spectrum blockers toward sophisticated precision approaches aimed at triggering synthetic lethality. Preclinical advances include strategies that deliberately hyperactivate mitochondrial activity, trigger cupropstosis or utilize Proteolysis Targeting Chimeras to eliminate proteins and transcription factors resistant to degradation. Translating these insights into clinical outcomes remains paramount. This requires a shift from rigid blockades to adaptable, patient specific interventions. By mapping the chaotic and highly localized metabolic nodes within the tumor microenvironment at single cell resolution, researchers can predictively model tumor evolution and disrupt metabolic plasticity of cancer and cancer stem cells in real time. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Bashir et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: